Loading...
XLONN4P
Market cap2mUSD
Dec 24, Last price  
0.53GBP
1D
0.00%
1Q
-12.50%
IPO
-99.25%
Name

N4 Pharma PLC

Chart & Performance

D1W1MN
XLON:N4P chart
P/E
—
P/S
106,123.66
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
21.61%
Rev. gr., 5y
-60.78%
Revenues
2k
1,659,0001,074,0001,398,0001,564,0001,977,0001,867,0001,919,0002,970,0002,678,0002,261,0001,364,00001,155,0000000001,953
Net income
-1m
L+23.32%
285,000-400,000515,000265,000260,000214,000364,000517,000136,000-156,000-2,394,000-1,053,000-22,000-1,836,984-1,184,843-876,373-1,304,843-1,544,346-1,029,261-1,269,331
CFO
-1m
L+45.98%
140,000-113,000-67,000160,000-184,000755,000249,000996,000-324,000-87,000-340,000-862,000-376,000-950,800-1,344,247-806,004-1,379,072-1,772,232-828,263-1,209,098
Dividend
May 19, 19970.005625 GBP/sh
Earnings
Apr 21, 2025

Profile

N4 Pharma Plc, a specialist pharmaceutical company, develops novel silica nanoparticle delivery system for pharmaceutical and biotechnology companies in the United Kingdom. It develops Nuvec, a non-viral adjuvant delivery system for vaccines and cancer treatments. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.
URL
https://www.n4pharma.com/
IPO date
Jun 07, 2005
Employees
5
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2
 
Cost of revenue
1,337
1,193
1,843
Unusual Expense (Income)
NOPBT
(1,335)
(1,193)
(1,843)
NOPBT Margin
Operating Taxes
(148)
(164)
(298)
Tax Rate
NOPAT
(1,188)
(1,029)
(1,545)
Net income
(1,269)
23.32%
(1,029)
-33.35%
(1,544)
18.35%
Dividends
Dividend yield
Proceeds from repurchase of equity
350
1,054
BB yield
-16.95%
-30.56%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
36
Net debt
(1,027)
(1,920)
(1,784)
Cash flow
Cash from operating activities
(1,209)
(828)
(1,772)
CAPEX
Cash from investing activities
781
Cash from financing activities
316
964
677
FCF
(1,124)
(852)
(1,789)
Balance
Cash
1,027
1,920
1,784
Long term investments
Excess cash
1,027
1,920
1,784
Stockholders' equity
178
(7,022)
(6,228)
Invested Capital
1,016
9,110
8,358
ROIC
ROCE
EV
Common stock shares outstanding
242,890
186,423
181,080
Price
0.01
-54.05%
0.02
-58.43%
0.04
-46.71%
Market cap
2,065
-40.14%
3,449
-57.20%
8,058
-29.20%
EV
1,103
1,529
6,274
EBITDA
(1,335)
(1,193)
(1,843)
EV/EBITDA
Interest
1
Interest/NOPBT